Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
Cagrilintide
AM833, CagriSema (in combination with semaglutide)
A long-acting amylin analog developed by Novo Nordisk. Amylin is a hormone co-secreted with insulin that regulates appetite and gastric emptying. Being developed both standalone and in combination with semaglutide (CagriSema) — a combination showing weight loss exceeding 22% in Phase 3 trials, potentially the next step beyond tirzepatide.
A non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide and tirzepatide which are peptides requiring injection, orforglipron is a fully oral pill taken once daily with no fasting requirement. Phase 3 trials are underway, potentially making it the first truly convenient oral GLP-1 option.
Activates amylin receptors (CALCR/RAMP) in the brain, particularly in the area postrema and hypothalamus, reducing appetite through a pathway distinct from GLP-1. The combination with semaglutide targets two separate appetite-regulating systems simultaneously, producing additive weight loss beyond either agent alone.
Activates GLP-1 receptors through a non-peptide chemical scaffold, producing the same downstream effects as injectable GLP-1 agonists — appetite suppression, insulin secretion, and slowed gastric emptying. The oral bioavailability is achieved through its small-molecule structure, unlike oral semaglutide (Rybelsus) which requires strict fasting protocols.
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic syndrome
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic health improvement
- GI side effects (nausea, vomiting) — similar to GLP-1 class
- Still in Phase 3 trials — full safety profile not established
- Injection site reactions
- Long-term effects unknown
- GI side effects (nausea, diarrhea, vomiting) — similar to injectable GLP-1s
- Still in Phase 3 trials — full safety profile not established
- Long-term cardiovascular outcomes data not yet available
- Not yet approved for any indication
Currently in Phase 3 trials as CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg). Phase 3 REDEFINE 1 trial showed ~22.7% weight loss at 68 weeks. Potential FDA submission 2026-2027. Represents the next generation beyond tirzepatide in the weight management pipeline.
Currently in Phase 3 clinical trials for obesity and type 2 diabetes. Phase 2 results showed ~14.7% weight loss at 36 weeks — comparable to injectable semaglutide. If approved, would be the first non-peptide oral GLP-1 agonist, removing the injection barrier for many patients. Potential approval 2026-2027.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.